ClinicalTrials.gg
CompletedNCT05419908Updated Nov 27, 2024Results posted

Trial to Investigate the Effect of ESN364 in Early Postmenopausal Women Suffering From Hot Flashes

A Phase 2 interventional study of Fezolinetant and Placebo in Hot Flashes, sponsored by Ogeda S.A.. Completed at 8 sites in Belgium. Open to female participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-11-27.

Sponsored by Ogeda S.A. (part of Astellas Pharma Inc) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 6 years 8 months after the study started (first participant enrolled Sep 2015, registered Jun 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
87
Allocation
Randomized
Ages
40 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing fezolinetant in Hot Flashes — 4 open to participants now, 5 under way, 4 of them phase 3. fezolinetant · Hot Flashes.

Enrollment
15th of 16
87 · median 249
Started
2015
the only one that year
Phase 2
5 of 16
1 open now
Registered
8th of 16
by date
Lead sponsor
1 of 16
Ogeda S.A.

Among the 16 studies testing fezolinetant in Hot Flashes, this one is the 15th largest by enrollment, is the only one that started in 2015, is one of 5 in phase 2, and was the 8th registered.

Hot Flashes

339 studies on the registry are indexed under Hot Flashes; 56 are open to participants now.

Browse Hot Flashes studies →

Open to participants now

4 of the 16 studies testing fezolinetant in Hot Flashes are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About fezolinetant

fezolinetant: first FDA approval 2023 (VEOZAH), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 36 Hot Flashes studies recruiting now, 13 (36%) set no upper age limit and 21 (58%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 40 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing fezolinetant in Hot Flashes, or all of them as a file.
02

Study summary

The primary purpose of this study was to evaluate the effect of ESN364 on the severity and frequency of hot flashes in early postmenopausal women suffering from hot flashes, in terms of changes in weekly Hot Flash Score from baseline to Week 12.

This study also evaluated the effect of ESN364 on the severity and frequency of hot flashes at additional timepoints; hot flash interference on daily life, in terms of changes from baseline over time in Hot Flash Related Daily Interference Scale (HFRDIS); the effect of ESN364 on climacteric symptoms, in terms of changes from baseline over time in Leeds Sleep Evaluation Questionnaire (LSEQ), Greene Climacteric Scale (GCS), and Sheehan Disability Scale (SDS); pharmacodynamic (PD) effect; and safety and tolerability.

03

Conditions studied

  • Hot Flashes

Browse trials for

Keywords

  • Hot flashes
  • ESN364
  • ASP2693
  • fezolinetant
  • menopause
  • postmenopausal
04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Spontaneous amenorrhea for at least 12 consecutive months; or spontaneous amenorrhea for at least 6 months with biochemical criteria of menopause (FSH >40 IU/L); or spontaneous amenorrhea for at least 3 months with biochemical/physical criteria of menopause (FSH >40 IU/L and E2 \<0.21 nmol/); or having had bilateral oophorectomy at least 6 weeks prior to screening (with or without hysterectomy);
  • At least 49 moderate or severe hot flashes or night sweats over a period of 7 consecutive days, as recorded in the daily diary during the screening period, with at least 4 of those days with 7 or more moderate or severe hot flashes per day;
  • In good general health as determined on the basis of medical history and general physical examination performed at screening; hematology and chemistry parameters, pulse rate and/or blood pressure, and within the reference range for the population studied, or showing no deviations;
  • Negative urine test for selected drugs of abuse (amphetamines, tricyclic antidepressants, cannabinoids, cocaine, tetrahydrocannabinol, or opiates) at screening;
  • Negative serology panel (including surface antigen [HBsAg], antihepatitis C virus [] and (HIV) antibody screens);
  • Negative urine pregnancy test at screening;

Exclusion criteria

Exclusion Criteria:

  • Use of a prohibited therapy or not willing to wash-out drugs considered prohibited therapies;
  • History (in the past year) or presence of drug or alcohol abuse;
  • Suicide attempt in the past 3 years;
  • Previous or current history of a malignant tumor (except basal cell carcinoma);
  • Active liver disease or jaundice, or out-of-range values of (ALT) and aspartate aminotransferase (AST); or total >1.3 times the (ULN); or creatinine >1.5 times the ULN; or estimated (eGFR) using the Modification of Diet in Renal Disease (MDRD) formula \<60 mL/min/1.73 m2 at screening;
  • Medical condition or chronic disease (including history of neurological [including cognitive], hepatic, renal, cardiovascular, gastrointestinal, pulmonary [e.g., moderate asthma], or endocrine disease) or that could confound interpretation of the study outcome;
  • Any psychological disorder according to the criteria indicated in the Diagnostics and Statistical Manual of Mental Disorders (DSM, 4th edition) within one year prior to screening. Such disorders include but are not limited to current major depression, alcohol (more than 3 glasses of wine, beer, or equivalent/day) or substance abuse/dependence;
  • Unsuited to participate in the study, based on findings observed during physical examination, vital sign assessment, or 12-lead ;
  • History of severe allergy, , or intolerance to drugs in general, including the study drug and any of its ;
  • Presence or sequellae of gastrointestinal, liver, kidney or other conditions known to interfere with the absorption, distribution, metabolism, or excretion (ADME) mechanisms of drugs;
  • Concurrent participation in another interventional study (or participation within 3 months prior to screening in this study);
  • History of poor compliance in clinical studies;
  • Unable or unwilling to complete the study procedures;
  • Subject is the Investigator or any sub-investigator, research assistant, pharmacist, study coordinator, or other staff or relative thereof who is directly involved in the conduct of the study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
87 participants (actual)

Study arms

  • Experimental
    Fezolinetant

    Participants received 90 milligrams (mg) fezolinetant capsules orally, twice daily (BID) for a period of 12 weeks

    Drug: Fezolinetant

  • Placebo comparator
    Placebo

    Participants received fezolinetant matching placebo capsules orally, BID for a period of 12 weeks.

    Drug: Placebo

Interventions

  • Oral Capsule

    Also known as: ESN364, ASP2693

  • DrugPlacebo

    Oral Capsule

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 12 in The Weekly General Hot Flash Score

    The HF score (based on severity and frequency) was calculated as: (number of mild HF/day × 1) + (number of moderate HF/day × 2) + (number of severe HF/day × 3) The severity of HFs is clinically defined as follows: * Mild: sensation of heat without sweating/dampness. If at night, participant didn't wake up but later notices damp sheets or clothing. * Moderate: Sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. * Severe: Sensation of intense heat with sweating, causing disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., removing layers of clothes, open the window, or get out of bed). Higher scores indicate worse symptoms. There is no maximum score since the score was participant dependent for both number and severity.

    Time frame: Baseline and week 12

Secondary outcomes

  1. Change From Baseline in The Weekly Hot Flash Severity Score at Weeks 4, 8 and 12 (Method 1)

    The HF Severity Score by method 1 takes into account the number and severity of moderate and severe HF occurred during a given time period and was calculated as follows HF Severity score = \[(number of moderate HF/day × 2) + (number of severe HF/day × 3)\]/(number of moderate HF + number of severe HF) The severity of HFs was clinically defined as follows: * Moderate: Sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. * Severe: Sensation of intense heat with sweating, causing disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., removing layers of clothes, open the window, or get out of bed). Higher scores indicate worse symptoms. There is no maximum score since the score was participant-dependent for both number and severity.

    Time frame: Baseline and weeks 4, 8 and 12

  2. Change From Baseline in The Weekly Hot Flash Severity Score at Weeks 4, 8 and 12 (Method 2)

    The HF Severity Score by method 2 takes into account moderate and severe HF during a given time period and was calculated as follows HF Severity score = \[(number of moderate HF/day × 2) + (number of severe HF/day × 3)\] The severity of HFs was clinically defined as follows: * Moderate: Sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. * Severe: Sensation of intense heat with sweating, causing disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., removing layers of clothes, open the window, or get out of bed). Higher scores indicate worse symptoms. There is no maximum score since the score was participant-dependent for both number and severity.

    Time frame: Baseline and weeks 4, 8 and 12

  3. Change From Baseline in The Weekly Mild, Moderate and Severe Hot Flash Frequency at Weeks 4, 8 and 12

    The weekly HF frequency was calculated as number of mild, moderate and severe hot flashes over the week. * Mild: sensation of heat without sweating/dampness. If at night, participant didn't wake up but later notices damp sheets or clothing. * Moderate: Sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. * Severe: Sensation of intense heat with sweating, causing disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., removing layers of clothes, open the window, or get out of bed). Higher number of hot flashes is worse.

    Time frame: Baseline and weeks 4, 8 and 12

  4. Percentage of Participants With >=70% Reduction in the Weekly Hot Flash Score From Baseline to Weeks 4, 8 and 12

    The HF score (based on severity and frequency) was calculated as: (number of mild HF/day × 1) + (number of moderate HF/day × 2) + (number of severe HF/day × 3) The severity of HFs is clinically defined as follows: * Mild: sensation of heat without sweating/dampness. If at night, participant didn't wake up but later notices damp sheets or clothing. * Moderate: Sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. * Severe: Sensation of intense heat with sweating, causing disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., removing layers of clothes, open the window, or get out of bed). Higher scores indicate worse symptoms. There is no maximum score since the score was participant-dependent for both number and severity.

    Time frame: Baseline and weeks 4, 8 and 12

  5. Percentage of Participants With >=80% Reduction in the Weekly Hot Flash Score From Baseline to Weeks 4, 8 and 12

    The HF score (based on severity and frequency) was calculated as: (number of mild HF/day × 1) + (number of moderate HF/day × 2) + (number of severe HF/day × 3) The severity of HFs is clinically defined as follows: * Mild: sensation of heat without sweating/dampness. If at night, participant didn't wake up but later notices damp sheets or clothing. * Moderate: Sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. * Severe: Sensation of intense heat with sweating, causing disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., removing layers of clothes, open the window, or get out of bed). Higher scores indicate worse symptoms. There is no maximum score since the score was participant-dependent for both number and severity.

    Time frame: Baseline and weeks 4, 8 and 12

  6. Percentage of Participants With >=90% Reduction in the Weekly Hot Flash Score From Baseline to Weeks 4, 8 and 12

    The HF score (based on severity and frequency) was calculated as: (number of mild HF/day × 1) + (number of moderate HF/day × 2) + (number of severe HF/day × 3) The severity of HF is clinically defined as follows: * Mild: sensation of heat without sweating/dampness. If at night, participant didn't wake up but later notices damp sheets or clothing. * Moderate: Sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. * Severe: Sensation of intense heat with sweating, causing disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., removing layers of clothes, open the window, or get out of bed). Higher scores indicate worse symptoms. There is no maximum score since the score was participant-dependent for both number and severity.

    Time frame: Baseline and weeks 4, 8 and 12

  7. Percentage of Participants With >=50% Reduction in the Weekly Frequency of Moderate and Severe HF From Baseline to Weeks 4, 8 and 12

    The weekly HF frequency of moderate and severe HF was calculated as number of moderate and severe HF over the week. * Moderate: Sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. * Severe: Sensation of intense heat with sweating, causing disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., removing layers of clothes, open the window, or get out of bed). Higher number of HF indicates worse symptoms.

    Time frame: Baseline and weeks 4, 8 and 12

  8. Percentage of Participants With >=70% Reduction in the Weekly Frequency of Moderate and Severe HF From Baseline to Weeks 4, 8 and 12

    The weekly HF frequency of moderate and severe HF was calculated as number of moderate and severe HF over the week. * Moderate: Sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. * Severe: Sensation of intense heat with sweating, causing disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., removing layers of clothes, open the window, or get out of bed). Higher number of HF indicates worse symptoms.

    Time frame: Baseline and weeks 4, 8 and 12

  9. Percentage of Participants With >=90% Reduction in the Weekly Frequency of Moderate and Severe HF From Baseline to Weeks 4, 8 and 12

    The weekly HF frequency of moderate and severe HF was calculated as number of moderate and severe HF over the week. * Moderate: Sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. * Severe: Sensation of intense heat with sweating, causing disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., removing layers of clothes, open the window, or get out of bed). Higher number of HF indicates worse symptoms.

    Time frame: Baseline and weeks 4, 8 and 12

  10. Change From Baseline in Hot Flash Related Daily Interference Scale (HFRDIS) Score at Weeks 4, 8 and 12

    The HFRDIS was a 10-item scale which measured a woman's perceptions of the degree to which HF interfere with 9 daily life activities (work, social activities, leisure, sleep, mood, concentration, relations with others, sexuality, enjoying life); the 10th item measures interference with overall quality of life. This scale was modeled after items on the Brief Pain Inventory and Brief Fatigue Inventory both of which assessed the extent to which pain or fatigue interfere with daily life. Participants were asked to rate the extent to which HF had interfered with each item during the previous 4-week time interval using a 0 (do not interfere) to 10 (completely interfere) scale. Overall mean score was calculated as sum of items/number of available items. Higher score indicate a higher interference.

    Time frame: Baseline and weeks 4, 8 and 12

  11. Change From Baseline in Leeds Sleep Evaluation Questionnaire (LSEQ) at Weeks 4, 8 and 12

    The LSEQ was a 10-item self-rated questionnaire which assessed participants aspects of sleep and early morning behavior. The questions were grouped into 4 chronological areas: the ease of getting to sleep, the perceived quality of sleep, the ease of awaking from sleep, and the integrity of early morning behavior following wakefulness. The LSEQ was a visual analogue scale which requires respondents to place marks on a group of 10 cm lines. representing the changes they have experienced in a variety of symptoms since the beginning of treatment. Lines extends between extremes like "more difficult than usual" and "easier than usual". Responses are measured using a 100-mm scale and are averaged to provide a score for each domain.

    Time frame: Baseline and weeks 4, 8 and 12

  12. Change From Baseline in Greene Climacteric Scale (GCS) at Weeks 4, 8 and 12

    The GCS was a 21-item scale which provides a brief but comprehensive and valid measure of climacteric symptomatology. Each item was rated by the participant according to its severity using a four-point rating scale from 0 (none) to 3 (severe). The first 20 items of the scale combine into three main independent symptom measures: psychological symptoms (items 1 to 11; score 0 to 33), physical symptoms (items 12 to 18; score 0 to 21), and vasomotor symptoms (items 19 to 20; score 0 to 6), by summing up the individual item scores. Item 21 is a probe for sexual dysfunction (Loss of interest in sex). The total score ranges from 0 to 63. Higher scores indicate worse symptoms.

    Time frame: Baseline and weeks 4, 8 and 12

  13. Change From Baseline in Sheehan Disability Scale (SDS) at Weeks 4, 8 and 12

    The SDS was a composite of 3 self-rated items designed to measure the extent to which 3 major sectors in a participant's life are impaired by panic, anxiety, phobic, or depressive symptoms. The participant rates the extent to which his/her 1- work/school, 2- social life, and 3- family life are impaired by his/her symptoms on a 10-point visual analog scale. The 3 items could be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired).Higher scores indicate significant functional impairment.

    Time frame: Baseline and weeks 4, 8 and 12

  14. Change From Baseline in Sheehan Disability Scale (SDS) at Weeks 4, 8 and 12 (Days Lost and Days Unproductive)

    The SDS was a composite of 3 self-rated items designed to measure the extent to which 3 major sectors in a participant's life are impaired by panic, anxiety, phobic, or depressive symptoms. The participant rates the extent to which his/her 1- work/school, 2- social life, and 3- family life are impaired by his/her symptoms. In addition to the 3 items, the participants were asked two questions Days Lost: On how many days in the last week did your symptoms cause you to miss school or work or leave you unable to carry out your normal daily responsibilities? Day Unproductive: On how many days in the last week did you feel so impaired by your symptoms, that even though you went to school or work, your productivity was reduced?

    Time frame: Baseline and weeks 4, 8 and 12

  15. Change From Baseline in Plasma Concentration of Luteinizing Hormone (LH)

    Change From baseline in plasma concentration of LH was reported.

    Time frame: Baseline and week 4: pre-dose, week 8:pre-dose, week 12:pre-dose, week 12: 3h, follow-up (week 15)

  16. Change From Baseline in Plasma Concentration of Follicle-Stimulating Hormone (FSH)

    Change From baseline in plasma concentration of FSH was reported.

    Time frame: Baseline and week 4: pre-dose, week 8:pre-dose, week 12:pre-dose, week 12:3h, follow-up (week 15)

  17. Change From Baseline in Plasma Concentration of Estradiol (E2)

    Change From baseline in plasma concentration of E2 was reported.

    Time frame: Baseline and week 4: pre-dose, week 8:pre-dose, week 12:pre-dose, week 12:3h, follow-up (week 15)

  18. Change From Baseline in Plasma Concentration of Sex Hormone-Binding Globulin (SHBG)

    Change From baseline in plasma concentration of SHBG was reported.

    Time frame: Baseline and week 4: pre-dose, week 8:pre-dose, week 12:pre-dose, week 12:3h, follow-up (week 15)

  19. Change From Baseline in Plasma Concentration of Leptin

    Change From baseline in plasma concentration of leptin was reported.

    Time frame: Baseline and week 4: pre-dose, week 8:pre-dose, week 12:pre-dose, week 12:3h, follow-up (week 15)

  20. Change From Baseline in Plasma Concentration of Insulin

    Change From baseline in plasma concentration of insulin was reported.

    Time frame: Baseline and week 4: pre-dose, week 8:pre-dose, week 12:pre-dose, week 12:3h, follow-up (week 15)

  21. Change From Baseline in Plasma Concentration of C-peptide

    Change From baseline in plasma concentration of C-peptide was reported.

    Time frame: Baseline and week 4: pre-dose, week 8:pre-dose, week 12:pre-dose, week 12:3h, follow-up (week 15)

  22. Change From Baseline in Plasma Concentration of Glycated Hemoglobin (HBA1c)

    Change From baseline in plasma concentration of HBA1C was reported.

    Time frame: Baseline and week 12

  23. Number of Participants With Adverse Events (AE's)

    An AE is any untoward medical occurrence in a participant administered a study drug, \& which does not necessarily have to have a causal relationship with treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with use of a medicinal product (mp) whether or not considered related to the mp. An AE is considered "serious" if it results in death, is life-threatening, results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, results in congenital anomaly or birth defect, requires inparticipant hospitalization or leads to prolongation of hospitalization, hospitalization for treatment/observation/examination caused by AE is to be considered as serious, discontinuation due to increases in liver enzymes, other medically important events. TEAE was defined as an AE observed from first dose date up to end of study.

    Time frame: From first dose of study drug until end of the study (Up to week 15)

  24. Change From Baseline in Plasma Concentration of Bone Alkaline Phosphatase (BALP) at Week 12

    Change from baseline in plasma concentration of BALP was reported.

    Time frame: Baseline and week 12

  25. Change From Baseline in Plasma Concentration of Carboxy-terminal Telopeptide of Type I Collagen (CTX) at Week 12

    Change from baseline in plasma concentration of CTX was reported.

    Time frame: Baseline and week 12

07

Results

Posted Jul 25, 2023

Participant flow

Postmenopausal women participants between 40 to 65 years of age who had hot flashes (HF) and who met the inclusion criteria and none of the exclusion criteria were enrolled in this study.

Participant flow — Overall Study
MilestonePlaceboFezolinetant
Started4443
Completed4040
Not completed43
Withdrew: Participant did not fulfill all inclusion/exclusion criteria10
Withdrew: Serious adverse event02
Withdrew: Withdrawal by subject20
Withdrew: Miscellaneous11

Outcome measures

PrimaryChange From Baseline to Week 12 in The Weekly General Hot Flash Score

The HF score (based on severity and frequency) was calculated as: (number of mild HF/day × 1) + (number of moderate HF/day × 2) + (number of severe HF/day × 3) The severity of HFs is clinically defined as follows: * Mild: sensation of heat without sweating/dampness. If at night, participant didn't wake up but later notices damp sheets or clothing. * Moderate: Sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. * Severe: Sensation of intense heat with sweating, causing disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., removing layers of clothes, open the window, or get out of bed). Higher scores indicate worse symptoms. There is no maximum score since the score was participant dependent for both number and severity.

Time frame:
Baseline and week 12
Reported as:
Mean · score on a scale
Change From Baseline to Week 12 in The Weekly General Hot Flash Score
score on a scalePlaceboFezolinetant
Change From Baseline to Week 12 in The Weekly General Hot Flash Score-12.19 (-16.55 to -7.83)-26.51 (-30.83 to -22.18)
Statistical analysis
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square (LS) mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline weekly hot flash score as covariate. P-value of the t-statistic testing whether there is a treatment difference.) · Lsmean difference: -12.34 · 95% CI -16.89 to -7.79Analysis of Covariance (ANCOVA)
SecondaryChange From Baseline in The Weekly Hot Flash Severity Score at Weeks 4, 8 and 12 (Method 1)

The HF Severity Score by method 1 takes into account the number and severity of moderate and severe HF occurred during a given time period and was calculated as follows HF Severity score = \[(number of moderate HF/day × 2) + (number of severe HF/day × 3)\]/(number of moderate HF + number of severe HF) The severity of HFs was clinically defined as follows: * Moderate: Sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. * Severe: Sensation of intense heat with sweating, causing disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., removing layers of clothes, open the window, or get out of bed). Higher scores indicate worse symptoms. There is no maximum score since the score was participant-dependent for both number and severity.

Time frame:
Baseline and weeks 4, 8 and 12
Reported as:
Mean · score on a scale
Change From Baseline in The Weekly Hot Flash Severity Score at Weeks 4, 8 and 12 (Method 1)
score on a scalePlaceboFezolinetant
Week 4-0.294 (-0.473 to -0.116)-1.428 (-1.718 to -1.138)
Week 8-0.608 (-0.899 to -0.318)-1.557 (-1.858 to -1.257)
Week 12-0.534 (-0.798 to -0.270)-1.656 (-1.937 to -1.376)
Statistical analysis
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline weekly hot flash score as covariate. P-value of the t-statistic testing whether there is a treatment difference.) · Lsmean difference: -1.134 · 95% CI -1.466 to -0.802
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline weekly hot flash score as covariate. P-value of the t-statistic testing whether there is a treatment difference.) · Lsmean difference: -0.948 · 95% CI -1.362 to -0.535
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline weekly hot flash score as covariate. P-value of the t-statistic testing whether there is a treatment difference.) · Lsmean difference: -1.122 · 95% CI -1.504 to -0.741
SecondaryChange From Baseline in The Weekly Hot Flash Severity Score at Weeks 4, 8 and 12 (Method 2)

The HF Severity Score by method 2 takes into account moderate and severe HF during a given time period and was calculated as follows HF Severity score = \[(number of moderate HF/day × 2) + (number of severe HF/day × 3)\] The severity of HFs was clinically defined as follows: * Moderate: Sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. * Severe: Sensation of intense heat with sweating, causing disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., removing layers of clothes, open the window, or get out of bed). Higher scores indicate worse symptoms. There is no maximum score since the score was participant-dependent for both number and severity.

Time frame:
Baseline and weeks 4, 8 and 12
Reported as:
Mean · score on a scale
Change From Baseline in The Weekly Hot Flash Severity Score at Weeks 4, 8 and 12 (Method 2)
score on a scalePlaceboFezolinetant
Week 4-9.55 (-12.73 to -6.36)-25.26 (-29.64 to -20.89)
Week 8-11.91 (-15.72 to -8.10)-25.71 (-30.15 to -21.27)
Week 12-12.14 (-16.62 to -7.65)-26.61 (-31.06 to -22.17)
Statistical analysis
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline weekly hot flash score as covariate. P-value of the t-statistic testing whether there is a treatment difference.) · Lsmean difference: -13.28 · 95% CI -17.02 to -9.54
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline weekly hot flash score as covariate. P-value of the t-statistic testing whether there is a treatment difference.) · Lsmean difference: -11.78 · 95% CI -16.30 to -7.27
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline weekly hot flash score as covariate. P-value of the t-statistic testing whether there is a treatment difference.) · Lsmean difference: -12.42 · 95% CI -17.00 to -7.83
SecondaryChange From Baseline in The Weekly Mild, Moderate and Severe Hot Flash Frequency at Weeks 4, 8 and 12

The weekly HF frequency was calculated as number of mild, moderate and severe hot flashes over the week. * Mild: sensation of heat without sweating/dampness. If at night, participant didn't wake up but later notices damp sheets or clothing. * Moderate: Sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. * Severe: Sensation of intense heat with sweating, causing disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., removing layers of clothes, open the window, or get out of bed). Higher number of hot flashes is worse.

Time frame:
Baseline and weeks 4, 8 and 12
Reported as:
Mean · HF's per day
Change From Baseline in The Weekly Mild, Moderate and Severe Hot Flash Frequency at Weeks 4, 8 and 12
HF's per dayPlaceboFezolinetant
Week 4-26.4 (-35.2 to -17.5)-72.3 (-82.7 to -61.8)
Week 8-32.9 (-43.2 to -22.7)-73.3 (-83.8 to -62.8)
Week 12-35.6 (-46.7 to -24.5)-75.3 (-86.4 to -64.3)
Statistical analysis
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as factor. P-value of the t-statistic testing whether there is a treatment difference.) · Lsmean difference: -39.8 · 95% CI -50.5 to -29.1
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as factor. P-value of the t-statistic testing whether there is a treatment difference.) · Lsmean difference: -35.5 · 95% CI -47.9 to -23.0
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as factor. P-value of the t-statistic testing whether there is a treatment difference.) · Lsmean difference: -35.0 · 95% CI -47.9 to -22.1
SecondaryPercentage of Participants With >=70% Reduction in the Weekly Hot Flash Score From Baseline to Weeks 4, 8 and 12

The HF score (based on severity and frequency) was calculated as: (number of mild HF/day × 1) + (number of moderate HF/day × 2) + (number of severe HF/day × 3) The severity of HFs is clinically defined as follows: * Mild: sensation of heat without sweating/dampness. If at night, participant didn't wake up but later notices damp sheets or clothing. * Moderate: Sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. * Severe: Sensation of intense heat with sweating, causing disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., removing layers of clothes, open the window, or get out of bed). Higher scores indicate worse symptoms. There is no maximum score since the score was participant-dependent for both number and severity.

Time frame:
Baseline and weeks 4, 8 and 12
Reported as:
Number · percentage of participants
Percentage of Participants With >=70% Reduction in the Weekly Hot Flash Score From Baseline to Weeks 4, 8 and 12
percentage of participantsPlaceboFezolinetant
Week 422.7 (10.34 to 35.11)87.8 (77.79 to 97.82)
Week 839.0 (24.09 to 53.96)87.5 (77.25 to 97.75)
Week 1242.5 (27.18 to 57.82)95.0 (88.25 to 100.00)
Statistical analysis
  • Placebo vs Fezolinetant · Likelihood-Ratio Chi-Square Test · p = <0.001 (Likelihood-ratio test based 95% confidence interval of the percentage difference.) · Percentage difference: 65.1 · 95% CI 49.15 to 81.00
  • Placebo vs Fezolinetant · Likelihood-Ratio Chi-Square Test · p = <0.001 (Likelihood-ratio test based 95% confidence interval of the percentage difference.) · Percentage difference: 48.5 · 95% CI 30.37 to 66.59
  • Placebo vs Fezolinetant · Likelihood-Ratio Chi-Square Test · p = <0.001 (Likelihood-ratio test based 95% confidence interval of the percentage difference.) · Percentage difference: 52.5 · 95% CI 35.76 to 69.24
SecondaryPercentage of Participants With >=80% Reduction in the Weekly Hot Flash Score From Baseline to Weeks 4, 8 and 12

The HF score (based on severity and frequency) was calculated as: (number of mild HF/day × 1) + (number of moderate HF/day × 2) + (number of severe HF/day × 3) The severity of HFs is clinically defined as follows: * Mild: sensation of heat without sweating/dampness. If at night, participant didn't wake up but later notices damp sheets or clothing. * Moderate: Sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. * Severe: Sensation of intense heat with sweating, causing disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., removing layers of clothes, open the window, or get out of bed). Higher scores indicate worse symptoms. There is no maximum score since the score was participant-dependent for both number and severity.

Time frame:
Baseline and weeks 4, 8 and 12
Reported as:
Number · percentage of participants
Percentage of Participants With >=80% Reduction in the Weekly Hot Flash Score From Baseline to Weeks 4, 8 and 12
percentage of participantsPlaceboFezolinetant
Week 49.1 (0.60 to 17.59)78.0 (65.38 to 90.72)
Week 826.8 (13.27 to 40.39)77.5 (64.56 to 90.44)
Week 1230.0 (15.80 to 44.20)87.5 (77.25 to 97.75)
Statistical analysis
  • Placebo vs Fezolinetant · Likelihood-Ratio Chi-Square Test · p = <0.001 (Likelihood-ratio test based 95% confidence interval of the percentage difference.) · Percentage difference: 69.0 · 95% CI 53.70 to 84.21
  • Placebo vs Fezolinetant · Likelihood-Ratio Chi-Square Test · p = <0.001 (Likelihood-ratio test based 95% confidence interval of the percentage difference) · Percentage difference: 50.7 · 95% CI 31.93 to 69.42
  • Placebo vs Fezolinetant · Likelihood-Ratio Chi-Square Test · p = <0.001 (Likelihood-ratio test based 95% confidence interval of the percentage difference) · Percentage difference: 57.5 · 95% CI 39.99 to 75.01
SecondaryPercentage of Participants With >=90% Reduction in the Weekly Hot Flash Score From Baseline to Weeks 4, 8 and 12

The HF score (based on severity and frequency) was calculated as: (number of mild HF/day × 1) + (number of moderate HF/day × 2) + (number of severe HF/day × 3) The severity of HF is clinically defined as follows: * Mild: sensation of heat without sweating/dampness. If at night, participant didn't wake up but later notices damp sheets or clothing. * Moderate: Sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. * Severe: Sensation of intense heat with sweating, causing disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., removing layers of clothes, open the window, or get out of bed). Higher scores indicate worse symptoms. There is no maximum score since the score was participant-dependent for both number and severity.

Time frame:
Baseline and weeks 4, 8 and 12
Reported as:
Number · percentage of participants
Percentage of Participants With >=90% Reduction in the Weekly Hot Flash Score From Baseline to Weeks 4, 8 and 12
percentage of participantsPlaceboFezolinetant
Week 46.8 (0.00 to 14.27)61.0 (46.04 to 75.91)
Week 812.2 (2.18 to 22.21)60.0 (44.82 to 75.18)
Week 1215.0 (3.93 to 26.07)62.5 (47.50 to 77.50)
Statistical analysis
  • Placebo vs Fezolinetant · Likelihood-Ratio Chi-Square Test · p = <0.001 (Likelihood-ratio test based 95% confidence interval of the percentage difference.) · Percentage difference: 54.2 · 95% CI 37.47 to 70.84
  • Placebo vs Fezolinetant · Likelihood-Ratio Chi-Square Test · p = <0.001 (Likelihood-ratio test based 95% confidence interval of the percentage difference.) · Percentage difference: 47.8 · 95% CI 29.62 to 65.99
  • Placebo vs Fezolinetant · Likelihood-Ratio Chi-Square Test · p = <0.001 (Likelihood-ratio test based 95% confidence interval of the percentage difference.) · Percentage difference: 47.5 · 95% CI 28.86 to 66.14
SecondaryPercentage of Participants With >=50% Reduction in the Weekly Frequency of Moderate and Severe HF From Baseline to Weeks 4, 8 and 12

The weekly HF frequency of moderate and severe HF was calculated as number of moderate and severe HF over the week. * Moderate: Sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. * Severe: Sensation of intense heat with sweating, causing disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., removing layers of clothes, open the window, or get out of bed). Higher number of HF indicates worse symptoms.

Time frame:
Baseline and weeks 4, 8 and 12
Reported as:
Number · percentage of participants
Percentage of Participants With >=50% Reduction in the Weekly Frequency of Moderate and Severe HF From Baseline to Weeks 4, 8 and 12
percentage of participantsPlaceboFezolinetant
Week 445.5 (30.74 to 60.17)95.1 (88.53 to 100.00)
Week 853.7 (38.39 to 68.92)97.5 (92.66 to 100.00)
Week 1255.0 (39.58 to 70.42)97.5 (92.66 to 100.00)
Statistical analysis
  • Placebo vs Fezolinetant · Likelihood-Ratio Chi-Square Test · p = <0.001 (Likelihood-ratio test based 95% confidence interval of the percentage difference.) · Percentage difference: 49.7 · 95% CI 33.54 to 65.79
  • Placebo vs Fezolinetant · Likelihood-Ratio Chi-Square Test · p = <0.001 (Likelihood-ratio test based 95% confidence interval of the percentage difference.) · Percentage difference: 43.8 · 95% CI 27.83 to 59.85
  • Placebo vs Fezolinetant · Likelihood-Ratio Chi-Square Test · p = <0.001 (Likelihood-ratio test based 95% confidence interval of the percentage difference.) · Percentage difference: 42.5 · 95% CI 26.34 to 58.66
SecondaryPercentage of Participants With >=70% Reduction in the Weekly Frequency of Moderate and Severe HF From Baseline to Weeks 4, 8 and 12

The weekly HF frequency of moderate and severe HF was calculated as number of moderate and severe HF over the week. * Moderate: Sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. * Severe: Sensation of intense heat with sweating, causing disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., removing layers of clothes, open the window, or get out of bed). Higher number of HF indicates worse symptoms.

Time frame:
Baseline and weeks 4, 8 and 12
Reported as:
Number · percentage of participants
Percentage of Participants With >=70% Reduction in the Weekly Frequency of Moderate and Severe HF From Baseline to Weeks 4, 8 and 12
percentage of participantsPlaceboFezolinetant
Week 425.0 (12.21 to 37.79)87.8 (77.79 to 97.82)
Week 846.3 (31.08 to 61.61)92.5 (84.34 to 100.00)
Week 1240.0 (24.82 to 55.18)97.5 (92.66 to 100.00)
Statistical analysis
  • Placebo vs Fezolinetant · Likelihood-Ratio Chi-Square Test · p = <0.001 (Likelihood-ratio test based 95% confidence interval of the percentage difference.) · Percentage difference: 62.8 · 95% CI 46.56 to 79.05
  • Placebo vs Fezolinetant · Likelihood-Ratio Chi-Square Test · p = <0.001 (Likelihood-ratio test based 95% confidence interval of the percentage difference.) · Percentage difference: 46.2 · 95% CI 28.85 to 63.47
  • Placebo vs Fezolinetant · Likelihood-Ratio Chi-Square Test · p = <0.001 (Likelihood-ratio test based 95% confidence interval of the percentage difference.) · Percentage difference: 57.5 · 95% CI 41.57 to 73.43
SecondaryPercentage of Participants With >=90% Reduction in the Weekly Frequency of Moderate and Severe HF From Baseline to Weeks 4, 8 and 12

The weekly HF frequency of moderate and severe HF was calculated as number of moderate and severe HF over the week. * Moderate: Sensation of heat with sweating/dampness, but was able to continue activity. If at night, participant woke up because she was feeling hot and/or was sweating, but no action was necessary other than rearranging the bed sheets. * Severe: Sensation of intense heat with sweating, causing disruption of activity. If at night, participant woke up hot and was sweating and needed to take action (e.g., removing layers of clothes, open the window, or get out of bed). Higher number of HF indicates worse symptoms.

Time frame:
Baseline and weeks 4, 8 and 12
Reported as:
Number · percentage of participants
Percentage of Participants With >=90% Reduction in the Weekly Frequency of Moderate and Severe HF From Baseline to Weeks 4, 8 and 12
percentage of participantsPlaceboFezolinetant
Week 46.8 (0.00 to 14.27)68.3 (54.05 to 82.54)
Week 824.4 (11.25 to 37.54)67.5 (52.99 to 82.01)
Week 1220.0 (7.60 to 32.40)72.5 (58.66 to 86.34)
Statistical analysis
  • Placebo vs Fezolinetant · Likelihood-Ratio Chi-Square Test · p = <0.001 (Likelihood-ratio test based 95% confidence interval of the percentage difference.) · Percentage difference: 61.5 · 95% CI 45.40 to 77.55
  • Placebo vs Fezolinetant · Likelihood-Ratio Chi-Square Test · p = <0.001 (Likelihood-ratio test based 95% confidence interval of the percentage difference.) · Percentage difference: 43.1 · 95% CI 23.53 to 62.69
  • Placebo vs Fezolinetant · Likelihood-Ratio Chi-Square Test · p = <0.001 (Likelihood-ratio test based 95% confidence interval of the percentage difference.) · Percentage difference: 52.5 · 95% CI 33.92 to 71.08
SecondaryChange From Baseline in Hot Flash Related Daily Interference Scale (HFRDIS) Score at Weeks 4, 8 and 12

The HFRDIS was a 10-item scale which measured a woman's perceptions of the degree to which HF interfere with 9 daily life activities (work, social activities, leisure, sleep, mood, concentration, relations with others, sexuality, enjoying life); the 10th item measures interference with overall quality of life. This scale was modeled after items on the Brief Pain Inventory and Brief Fatigue Inventory both of which assessed the extent to which pain or fatigue interfere with daily life. Participants were asked to rate the extent to which HF had interfered with each item during the previous 4-week time interval using a 0 (do not interfere) to 10 (completely interfere) scale. Overall mean score was calculated as sum of items/number of available items. Higher score indicate a higher interference.

Time frame:
Baseline and weeks 4, 8 and 12
Reported as:
Mean · score on a scale
Change From Baseline in Hot Flash Related Daily Interference Scale (HFRDIS) Score at Weeks 4, 8 and 12
score on a scalePlaceboFezolinetant
Week 4: Work-1.7 ± 2.93-4.6 ± 2.65
Week 8: Work-2.4 ± 2.80-5.0 ± 2.38
Week 12: Work-2.3 ± 2.58-4.6 ± 2.68
Week 4: Social Activities-1.6 ± 2.53-4.3 ± 2.48
Week 8: Social Activities-1.9 ± 2.85-4.7 ± 2.37
Week 12: Social Activities-1.8 ± 2.51-4.3 ± 2.35
Week 4: Leisure Activities-1.6 ± 2.63-4.0 ± 2.51
Week 8: Leisure Activities-1.7 ± 2.72-4.2 ± 2.50
Week 12: Leisure Activities-2.0 ± 2.52-3.8 ± 3.08
Week 4: Sleep-2.5 ± 2.93-5.2 ± 2.77
Week 8: Sleep-3.2 ± 3.29-5.7 ± 2.37
Week 12: Sleep-3.3 ± 3.01-5.8 ± 2.43
Week 4: Mood-2.3 ± 2.49-4.0 ± 2.85
Week 8: Mood-2.3 ± 2.86-4.4 ± 2.84
Week 12: Mood-2.5 ± 2.56-4.3 ± 2.64
Week 4: Concentration-1.6 ± 2.68-3.9 ± 2.57
Week 8: Concentration-1.6 ± 3.06-4.1 ± 2.59
Week 12: Concentration-1.9 ± 3.17-4.0 ± 2.47
Week 4: Relations With Others-2.1 ± 2.93-3.3 ± 2.45
Week 8: Relations With Others-1.8 ± 3.02-3.5 ± 2.70
Week 12: Relations With Others-1.8 ± 3.16-3.3 ± 2.67
Week 4: Sexuality-1.9 ± 2.88-3.0 ± 3.49
Week 8: Sexuality-1.8 ± 3.48-3.2 ± 3.76
Week 12: Sexuality-1.7 ± 2.84-3.4 ± 3.86
Week 4: Enjoyment of Life-1.6 ± 2.86-3.6 ± 2.65
Week 8: Enjoyment of Life-1.5 ± 3.15-3.9 ± 2.59
Week 12: Enjoyment of Life-1.6 ± 3.38-3.7 ± 2.42
Week 4: Overall Quality of Life-1.4 ± 2.43-3.8 ± 2.87
Week 8: Overall Quality of Life-1.5 ± 3.01-4.5 ± 1.92
Week 12: Overall Quality of Life-1.6 ± 3.05-4.6 ± 2.16
Week 4: Overall Mean Score-1.84 ± 1.922-3.97 ± 2.141
Week 8: Overall Mean Score-1.98 ± 2.439-4.33 ± 1.945
Week 12: Overall Mean Score-2.05 ± 2.326-4.17 ± 2.067
Statistical analysis
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline weekly hfrdis as covariate.) · Lsmean difference: -2.53 · 95% CI -3.45 to -1.60
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline weekly hfrdis as covariate.) · Lsmean difference: -2.29 · 95% CI -3.15 to -1.42
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline weekly hfrdis as covariate.) · Lsmean difference: -2.11 · 95% CI -3.03 to -1.20
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline weekly hfrdis as covariate.) · Lsmean difference: -2.33 · 95% CI -3.19 to -1.46
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline weekly hfrdis as covariate.) · Lsmean difference: -2.34 · 95% CI -3.21 to -1.47
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline weekly hfrdis as covariate.) · Lsmean difference: -2.19 · 95% CI -3.09 to -1.29
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline weekly hfrdis as covariate.) · Lsmean difference: -2.15 · 95% CI -2.99 to -1.31
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline weekly hfrdis as covariate.) · Lsmean difference: -2.37 · 95% CI -3.19 to -1.55
  • Placebo vs Fezolinetant · ANCOVA · p = 0.002 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline weekly hfrdis as covariate.) · Lsmean difference: -1.64 · 95% CI -2.66 to -0.62
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline weekly hfrdis as covariate.) · Lsmean difference: -2.93 · 95% CI -4.08 to -1.78
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline weekly hfrdis as covariate.) · Lsmean difference: -2.71 · 95% CI -3.86 to -1.57
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline weekly hfrdis as covariate.) · Lsmean difference: -2.61 · 95% CI -3.67 to -1.54
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline weekly hfrdis as covariate.) · Lsmean difference: -1.74 · 95% CI -2.67 to -0.81
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline weekly hfrdis as covariate.) · Lsmean difference: -2.12 · 95% CI -3.09 to -1.16
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline weekly hfrdis as covariate.) · Lsmean difference: -1.79 · 95% CI -2.69 to -0.88
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline weekly hfrdis as covariate.) · Lsmean difference: -1.92 · 95% CI -2.86 to -0.97
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline weekly hfrdis as covariate.) · Lsmean difference: -2.23 · 94% CI -3.21 to -1.25
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline weekly hfrdis as covariate.) · Lsmean difference: -1.90 · 95% CI -2.91 to -0.88
  • Placebo vs Fezolinetant · ANCOVA · p = 0.003 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline weekly hfrdis as covariate.) · Lsmean difference: -1.33 · 95% CI -2.20 to -0.46
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline weekly hfrdis as covariate.) · Lsmean difference: -1.85 · 95% CI -2.80 to -0.90
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline weekly hfrdis as covariate.) · Lsmean difference: -1.72 · 95% CI -2.66 to -0.77
  • Placebo vs Fezolinetant · ANCOVA · p = 0.081 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline weekly hfrdis as covariate.) · Lsmean difference: -1.06 · 95% CI -2.25 to 0.13
  • Placebo vs Fezolinetant · ANCOVA · p = 0.050 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline weekly hfrdis as covariate.) · Lsmean difference: -1.40 · 95% CI -2.80 to 0.00
  • Placebo vs Fezolinetant · ANCOVA · p = 0.026 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline weekly hfrdis as covariate.) · Lsmean difference: -1.51 · 95% CI -2.84 to -0.19
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline weekly hfrdis as covariate.) · Lsmean difference: -1.65 · 95% CI -2.51 to -0.79
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline weekly hfrdis as covariate.) · Lsmean difference: -2.07 · 95% CI -2.97 to -1.18
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline weekly hfrdis as covariate.) · Lsmean difference: -1.83 · 95% CI -2.88 to -0.78
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline weekly hfrdis as covariate.) · Lsmean difference: -1.92 · 95% CI -2.86 to -0.97
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline weekly hfrdis as covariate.) · Lsmean difference: -2.51 · 95% CI -3.41 to -1.61
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline weekly hfrdis as covariate.) · Lsmean difference: -2.36 · 95% CI -3.31 to -1.41
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline weekly hfrdis as covariate.) · Lsmean difference: -1.98 · 95% CI -2.73 to -1.23
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline weekly hfrdis as covariate.) · Lsmean difference: -2.21 · 95% CI -3.02 to -1.40
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline weekly hfrdis as covariate.) · Lsmean difference: -1.98 · 95% CI -2.83 to -1.13
SecondaryChange From Baseline in Leeds Sleep Evaluation Questionnaire (LSEQ) at Weeks 4, 8 and 12

The LSEQ was a 10-item self-rated questionnaire which assessed participants aspects of sleep and early morning behavior. The questions were grouped into 4 chronological areas: the ease of getting to sleep, the perceived quality of sleep, the ease of awaking from sleep, and the integrity of early morning behavior following wakefulness. The LSEQ was a visual analogue scale which requires respondents to place marks on a group of 10 cm lines. representing the changes they have experienced in a variety of symptoms since the beginning of treatment. Lines extends between extremes like "more difficult than usual" and "easier than usual". Responses are measured using a 100-mm scale and are averaged to provide a score for each domain.

Time frame:
Baseline and weeks 4, 8 and 12
Reported as:
Mean · millimeter (mm)
Change From Baseline in Leeds Sleep Evaluation Questionnaire (LSEQ) at Weeks 4, 8 and 12
millimeter (mm)PlaceboFezolinetant
Week 4: Getting to Sleep1.017 ± 1.91952.283 ± 2.7364
Week 8: Getting to Sleep1.145 ± 1.79312.248 ± 2.5233
Week 12: Getting to Sleep1.282 ± 1.77612.094 ± 2.4419
Week 4: Quality of Sleep2.145 ± 2.64434.437 ± 4.0768
Week 8: Quality of Sleep2.378 ± 2.81604.703 ± 3.1971
Week 12: Quality of Sleep1.904 ± 2.78724.385 ± 3.4477
Week 4: Awake Following Sleep0.642 ± 2.07392.180 ± 3.0579
Week 8: Awake Following Sleep0.653 ± 2.50192.920 ± 3.0219
Week 12: Awake Following Sleep1.024 ± 2.61142.887 ± 3.1333
Week 4: Behavior Following Wakening1.173 ± 2.17432.513 ± 2.7919
Week 8: Behavior Following Wakening0.750 ± 2.63712.539 ± 2.7742
Week 12: Behavior Following Wakening1.203 ± 2.51852.233 ± 2.8190
Statistical analysis
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline LSEQ as covariate.) · Lsmean difference: 1.375 · 95% CI 0.651 to 2.100
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline LSEQ as covariate.) · Lsmean difference: 1.166 · 95% CI 0.505 to 1.827
  • Placebo vs Fezolinetant · ANCOVA · p = 0.014 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline LSEQ as covariate.) · Lsmean difference: 0.895 · 95% CI 0.190 to 1.599
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline LSEQ as covariate.) · Lsmean difference: 2.423 · 95% CI 1.308 to 3.539
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline LSEQ as covariate.) · Lsmean difference: 2.291 · 95% CI 1.31 to 3.251
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline LSEQ as covariate.) · Lsmean difference: 2.433 · 95% CI 1.334 to 3.532
  • Placebo vs Fezolinetant · ANCOVA · p = 0.059 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline LSEQ as covariate.) · Lsmean difference: 0.877 · 95% CI -0.034 to 1.789
  • Placebo vs Fezolinetant · ANCOVA · p = 0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline LSEQ as covariate.) · Lsmean difference: 1.457 · 95% CI 0.579 to 2.335
  • Placebo vs Fezolinetant · ANCOVA · p = 0.031 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline LSEQ as covariate.) · Lsmean difference: 1.113 · 95% CI 0.107 to 2.120
  • Placebo vs Fezolinetant · ANCOVA · p = 0.008 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline LSEQ as covariate.) · Lsmean difference: 1.203 · 95% CI 0.317 to 2.088
  • Placebo vs Fezolinetant · ANCOVA · p = 0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline LSEQ as covariate.) · Lsmean difference: 1.597 · 95% CI 0.639 to 2.556
  • Placebo vs Fezolinetant · ANCOVA · p = 0.084 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline LSEQ as covariate.) · Lsmean difference: 0.842 · 95% CI -0.116 to 1.800
SecondaryChange From Baseline in Greene Climacteric Scale (GCS) at Weeks 4, 8 and 12

The GCS was a 21-item scale which provides a brief but comprehensive and valid measure of climacteric symptomatology. Each item was rated by the participant according to its severity using a four-point rating scale from 0 (none) to 3 (severe). The first 20 items of the scale combine into three main independent symptom measures: psychological symptoms (items 1 to 11; score 0 to 33), physical symptoms (items 12 to 18; score 0 to 21), and vasomotor symptoms (items 19 to 20; score 0 to 6), by summing up the individual item scores. Item 21 is a probe for sexual dysfunction (Loss of interest in sex). The total score ranges from 0 to 63. Higher scores indicate worse symptoms.

Time frame:
Baseline and weeks 4, 8 and 12
Reported as:
Mean · score on a scale
Change From Baseline in Greene Climacteric Scale (GCS) at Weeks 4, 8 and 12
score on a scalePlaceboFezolinetant
Week 4: Loss of Interest in Sex-0.4 ± 0.67-0.5 ± 0.88
Week 8: Loss of interest in Sex-0.5 ± 0.85-0.7 ± 1.15
Week 12: Loss of Interest in Sex-0.4 ± 0.75-0.6 ± 1.14
Week 4: Psychological-2.3 ± 5.22-5.3 ± 5.97
Week 8: Psychological-2.6 ± 5.31-6.7 ± 6.49
Week 12: Psychological-2.9 ± 5.14-6.6 ± 6.03
Week 4: Physical-2.1 ± 3.68-1.2 ± 2.71
Week 8: Physical-1.9 ± 3.46-1.9 ± 3.09
Week 12: Physical-2.4 ± 3.80-1.9 ± 3.32
Week 4: Vasomotor-1.1 ± 1.79-3.3 ± 1.83
Week 8: Vasomotor-1.7 ± 2.23-3.6 ± 1.48
Week 12: Vasomotor-1.5 ± 2.31-3.6 ± 1.37
Week 4: Total Symptom Score-5.5 ± 9.33-9.9 ± 9.24
Week 8: Total Symptom Score-5.8 ± 8.89-13.1 ± 10.68
Week 12: Total Symptom Score-6.3 ± 8.87-13.1 ± 10.04
Statistical analysis
  • Placebo vs Fezolinetant · ANCOVA · p = 0.881 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline GCS as covariate.) · Lsmean difference: 0.00 · 95% CI -0.3 to 0.3
  • Placebo vs Fezolinetant · ANCOVA · p = 0.383 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline GCS as covariate.) · Lsmean difference: -0.2 · 95% CI -0.6 to 0.2
  • Placebo vs Fezolinetant · ANCOVA · p = 0.301 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline GCS as covariate.) · Lsmean difference: -0.2 · 95% CI -0.6 to 0.2
  • Placebo vs Fezolinetant · ANCOVA · p = 0.020 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline GCS as covariate.) · Lsmean difference: -2.5 · 95% CI -4.5 to -0.4
  • Placebo vs Fezolinetant · ANCOVA · p = 0.003 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline GCS as covariate.) · Lsmean difference: -3.3 · 95% CI -5.4 to -1.2
  • Placebo vs Fezolinetant · ANCOVA · p = 0.005 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline GCS as covariate.) · Lsmean difference: -3.1 · 95% CI -5.2 to -1.0
  • Placebo vs Fezolinetant · ANCOVA · p = 0.732 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline GCS as covariate.) · Lsmean difference: -0.2 · 95% CI -1.2 to 0.9
  • Placebo vs Fezolinetant · ANCOVA · p = 0.282 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline GCS as covariate.) · Lsmean difference: -0.7 · 95% CI -1.9 to 0.6
  • Placebo vs Fezolinetant · ANCOVA · p = 0.254 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline GCS as covariate.) · Lsmean difference: -0.6 · 95% CI -1.7 to 0.5
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline GCS as covariate.) · Lsmean difference: -2.0 · 95% CI -2.7 to -1.4
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline GCS as covariate.) · Lsmean difference: -1.8 · 95% CI -2.4 to -1.1
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline GCS as covariate.) · Lsmean difference: -2.0 · 95% CI -2.6 to -1.3
  • Placebo vs Fezolinetant · ANCOVA · p = 0.013 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline GCS as covariate.) · Lsmean difference: -4.6 · 95% CI -8.2 to -1.0
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline GCS as covariate.) · Lsmean difference: -6.9 · 95% CI -10.7 to -3.1
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline GCS as covariate.) · Lsmean difference: -6.3 · 95% CI -9.9 to -2.8
SecondaryChange From Baseline in Sheehan Disability Scale (SDS) at Weeks 4, 8 and 12

The SDS was a composite of 3 self-rated items designed to measure the extent to which 3 major sectors in a participant's life are impaired by panic, anxiety, phobic, or depressive symptoms. The participant rates the extent to which his/her 1- work/school, 2- social life, and 3- family life are impaired by his/her symptoms on a 10-point visual analog scale. The 3 items could be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired).Higher scores indicate significant functional impairment.

Time frame:
Baseline and weeks 4, 8 and 12
Reported as:
Mean · score on a scale
Change From Baseline in Sheehan Disability Scale (SDS) at Weeks 4, 8 and 12
score on a scalePlaceboFezolinetant
Week 4: Work/School-1.3 ± 2.43-3.6 ± 2.78
Week 8: Work/School-1.7 ± 2.56-4.4 ± 2.43
Week 12: Work/School-1.8 ± 2.76-4.3 ± 2.47
Week 4: Social Life-1.2 ± 2.35-3.3 ± 2.60
Week 8: Social Life-1.3 ± 2.57-3.8 ± 2.79
Week 12: Social Life-1.5 ± 2.55-3.6 ± 2.51
Week 4: Family Life/Home Responsibilities-1.5 ± 2.70-3.3 ± 2.97
Week 8: Family Life/Home Responsibilities-1.7 ± 2.64-4.0 ± 2.83
Week 12: Family Life/Home Responsibilities-1.7 ± 2.38-3.7 ± 2.65
Week 4: Global Functional Impairment-3.7 ± 5.50-9.6 ± 6.99
Week 8: Global Functional Impairment-4.5 ± 6.87-12.3 ± 6.42
Week 12: Global Functional Impairment-4.8 ± 6.49-11.8 ± 6.35
Statistical analysis
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline SDS as covariate.) · Lsmean difference: -1.7 · 95% CI -2.7 to -0.8
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline SDS as covariate.) · Lsmean difference: -2.0 · 95% CI -2.8 to -1.3
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline SDS as covariate.) · Lsmean difference: -1.6 · 95% CI -2.5 to -0.8
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline SDS as covariate.) · Lsmean difference: -1.4 · 95% CI -2.2 to -0.6
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline SDS as covariate.) · Lsmean difference: -1.9 · 95% CI -2.7 to -1.1
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline SDS as covariate.) · Lsmean difference: -1.6 · 95% CI -2.4 to -0.7
  • Placebo vs Fezolinetant · ANCOVA · p = 0.005 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline SDS as covariate.) · Lsmean difference: -1.3 · 95% CI -2.2 to -0.4
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline SDS as covariate.) · Lsmean difference: -1.7 · 95% CI -2.5 to -0.9
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline SDS as covariate.) · Lsmean difference: -1.6 · 95% CI -2.4 to -0.7
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline SDS as covariate.) · Lsmean difference: -4.4 · 95% CI -6.9 to -2.0
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline SDS as covariate.) · Lsmean difference: -5.8 · 95% CI -8.0 to -3.6
  • Placebo vs Fezolinetant · ANCOVA · p = <0.001 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline SDS as covariate.) · Lsmean difference: -5.3 · 95% CI -7.8 to -2.8
SecondaryChange From Baseline in Sheehan Disability Scale (SDS) at Weeks 4, 8 and 12 (Days Lost and Days Unproductive)

The SDS was a composite of 3 self-rated items designed to measure the extent to which 3 major sectors in a participant's life are impaired by panic, anxiety, phobic, or depressive symptoms. The participant rates the extent to which his/her 1- work/school, 2- social life, and 3- family life are impaired by his/her symptoms. In addition to the 3 items, the participants were asked two questions Days Lost: On how many days in the last week did your symptoms cause you to miss school or work or leave you unable to carry out your normal daily responsibilities? Day Unproductive: On how many days in the last week did you feel so impaired by your symptoms, that even though you went to school or work, your productivity was reduced?

Time frame:
Baseline and weeks 4, 8 and 12
Reported as:
Mean · days
Change From Baseline in Sheehan Disability Scale (SDS) at Weeks 4, 8 and 12 (Days Lost and Days Unproductive)
daysPlaceboFezolinetant
Week 4: Days Lost-0.2 ± 1.270.0 ± 0.73
Week 8: Days Lost-0.3 ± 0.810.0 ± 0.00
Week 12: Days Lost-0.2 ± 1.180.0 ± 0.00
Week 4: Days Unproductive-0.8 ± 2.83-1.7 ± 2.67
Week 8: Days Unproductive-1.2 ± 3.10-2.0 ± 2.55
Week 12: Days Unproductive-1.4 ± 2.82-2.2 ± 2.59
Statistical analysis
  • Placebo vs Fezolinetant · ANCOVA · p = 0.936 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline SDS as covariate.) · Lsmean difference: 0.00 · 95% CI -0.5 to 0.6
  • Placebo vs Fezolinetant · ANCOVA · p = 0.884 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline SDS as covariate.) · Lsmean difference: 0.0 · 95% CI -0.1 to 0.1
  • Placebo vs Fezolinetant · ANCOVA · p = 0.124 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline SDS as covariate.) · Lsmean difference: -0.2 · 95% CI -0.4 to 0.1
  • Placebo vs Fezolinetant · ANCOVA · p = 0.052 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline SDS as covariate.) · Lsmean difference: -0.9 · 95% CI -1.8 to 0.0
  • Placebo vs Fezolinetant · ANCOVA · p = 0.060 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline SDS as covariate.) · Lsmean difference: -0.9 · 95% CI -1.7 to 0.0
  • Placebo vs Fezolinetant · ANCOVA · p = 0.049 (Least square mean difference versus placebo, obtained from an ANCOVA model with treatment group as fixed effect and baseline SDS as covariate.) · Lsmean difference: -0.8 · 95% CI -1.7 to 0.0
SecondaryChange From Baseline in Plasma Concentration of Luteinizing Hormone (LH)

Change From baseline in plasma concentration of LH was reported.

Time frame:
Baseline and week 4: pre-dose, week 8:pre-dose, week 12:pre-dose, week 12: 3h, follow-up (week 15)
Reported as:
Mean · international unit per liter (IU/L)
Change From Baseline in Plasma Concentration of Luteinizing Hormone (LH)
international unit per liter (IU/L)PlaceboFezolinetant
Week 4: Pre-dose-2.34 ± 9.350-8.84 ± 10.865
Week 8: Pre-dose-3.86 ± 9.838-9.46 ± 13.647
Week 12: Pre-dose-4.61 ± 13.304-9.72 ± 12.834
Week 12: 3 hours (h)-7.16 ± 13.009-21.78 ± 11.923
Week 15-6.16 ± 14.197-3.33 ± 11.742
SecondaryChange From Baseline in Plasma Concentration of Follicle-Stimulating Hormone (FSH)

Change From baseline in plasma concentration of FSH was reported.

Time frame:
Baseline and week 4: pre-dose, week 8:pre-dose, week 12:pre-dose, week 12:3h, follow-up (week 15)
Reported as:
Mean · IU/L
Change From Baseline in Plasma Concentration of Follicle-Stimulating Hormone (FSH)
IU/LPlaceboFezolinetant
Week 4: Pre-dose-5.80 ± 19.430-3.44 ± 18.026
Week 8: Pre-dose-6.60 ± 20.086-10.36 ± 23.943
Week 12: Pre-dose-7.05 ± 19.978-10.51 ± 24.521
Week 12: 3h-8.47 ± 19.159-19.48 ± 22.734
Week 15-6.50 ± 21.011-6.97 ± 22.273
SecondaryChange From Baseline in Plasma Concentration of Estradiol (E2)

Change From baseline in plasma concentration of E2 was reported.

Time frame:
Baseline and week 4: pre-dose, week 8:pre-dose, week 12:pre-dose, week 12:3h, follow-up (week 15)
Reported as:
Mean · Picomoles per liter (pmol/L)
Change From Baseline in Plasma Concentration of Estradiol (E2)
Picomoles per liter (pmol/L)PlaceboFezolinetant
Week 4: Pre-dose18.4 ± 140.36-7.3 ± 75.13
Week 8: Pre-dose26.0 ± 157.181.0 ± 71.78
Week 12: Pre-dose32.3 ± 101.8725.5 ± 108.27
Week 12: 3h26.0 ± 100.3311.5 ± 77.68
Week 1537.0 ± 167.3727.9 ± 188.18
SecondaryChange From Baseline in Plasma Concentration of Sex Hormone-Binding Globulin (SHBG)

Change From baseline in plasma concentration of SHBG was reported.

Time frame:
Baseline and week 4: pre-dose, week 8:pre-dose, week 12:pre-dose, week 12:3h, follow-up (week 15)
Reported as:
Mean · Nanomoles per liter (nmol/L)
Change From Baseline in Plasma Concentration of Sex Hormone-Binding Globulin (SHBG)
Nanomoles per liter (nmol/L)PlaceboFezolinetant
Week 4: Pre-dose0.61 ± 16.260-0.47 ± 11.986
Week 8: Pre-dose5.10 ± 20.713-1.37 ± 12.186
Week 12: Pre-dose1.75 ± 18.0900.36 ± 15.165
Week 12: 3h1.56 ± 18.658-1.49 ± 16.406
Week 151.92 ± 16.341-0.86 ± 13.540
SecondaryChange From Baseline in Plasma Concentration of Leptin

Change From baseline in plasma concentration of leptin was reported.

Time frame:
Baseline and week 4: pre-dose, week 8:pre-dose, week 12:pre-dose, week 12:3h, follow-up (week 15)
Reported as:
Mean · nanogram per liter (ng/mL)
Change From Baseline in Plasma Concentration of Leptin
nanogram per liter (ng/mL)PlaceboFezolinetant
Week 4: Pre-dose1.2436 ± 5.6269-2.2185 ± 6.9522
Week 8: Pre-dose1.6225 ± 7.5029-1.7090 ± 6.9716
Week 12: Pre-dose0.9668 ± 5.4301-0.4183 ± 11.0737
Week 12: 3h-2.0755 ± 5.3193-4.2085 ± 8.5335
Week 15-0.9914 ± 14.6660-0.6031 ± 8.2519
SecondaryChange From Baseline in Plasma Concentration of Insulin

Change From baseline in plasma concentration of insulin was reported.

Time frame:
Baseline and week 4: pre-dose, week 8:pre-dose, week 12:pre-dose, week 12:3h, follow-up (week 15)
Reported as:
Mean · micro units per milliliter (μU/mL)
Change From Baseline in Plasma Concentration of Insulin
micro units per milliliter (μU/mL)PlaceboFezolinetant
Week 4: Pre-dose-0.2767 ± 3.0971-0.7512 ± 3.8798
Week 8: Pre-dose0.3525 ± 4.0903-0.5325 ± 3.6121
Week 12: Pre-dose-0.0825 ± 3.15930.1300 ± 4.7942
Week 12: 3h16.3225 ± 19.021014.4950 ± 19.2787
Week 150.3256 ± 4.1132-0.1595 ± 3.1071
SecondaryChange From Baseline in Plasma Concentration of C-peptide

Change From baseline in plasma concentration of C-peptide was reported.

Time frame:
Baseline and week 4: pre-dose, week 8:pre-dose, week 12:pre-dose, week 12:3h, follow-up (week 15)
Reported as:
Mean · ng/mL
Change From Baseline in Plasma Concentration of C-peptide
ng/mLPlaceboFezolinetant
Week 4: Pre-dose-0.0465 ± 0.3978-0.1463 ± 0.5134
Week 8: Pre-dose-0.0300 ± 0.5273-0.1175 ± 0.4750
Week 12: Pre-dose-0.0750 ± 0.5212-0.0425 ± 0.7154
Week 12: 3h2.1325 ± 1.99762.2875 ± 2.1811
Week 15-0.0047 ± 0.6102-0.0095 ± 0.4023
SecondaryChange From Baseline in Plasma Concentration of Glycated Hemoglobin (HBA1c)

Change From baseline in plasma concentration of HBA1C was reported.

Time frame:
Baseline and week 12
Reported as:
Mean · Percentage of HBA1c
Change From Baseline in Plasma Concentration of Glycated Hemoglobin (HBA1c)
Percentage of HBA1cPlaceboFezolinetant
Change From Baseline in Plasma Concentration of Glycated Hemoglobin (HBA1c)-0.00050000 ± 0.003162278-0.002307692 ± 0.004845800
SecondaryNumber of Participants With Adverse Events (AE's)

An AE is any untoward medical occurrence in a participant administered a study drug, \& which does not necessarily have to have a causal relationship with treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with use of a medicinal product (mp) whether or not considered related to the mp. An AE is considered "serious" if it results in death, is life-threatening, results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, results in congenital anomaly or birth defect, requires inparticipant hospitalization or leads to prolongation of hospitalization, hospitalization for treatment/observation/examination caused by AE is to be considered as serious, discontinuation due to increases in liver enzymes, other medically important events. TEAE was defined as an AE observed from first dose date up to end of study.

Time frame:
From first dose of study drug until end of the study (Up to week 15)
Reported as:
Number · participants
Number of Participants With Adverse Events (AE's)
participantsPlaceboFezolinetant
At least one TEAE3529
At least one serious TEAE10
At least one TEAE leading to death00
At least one severe TEAE00
At least one TEAE for which the study treatment was permanently stopped02
At least one TEAE that was considered treatment related1113
SecondaryChange From Baseline in Plasma Concentration of Bone Alkaline Phosphatase (BALP) at Week 12

Change from baseline in plasma concentration of BALP was reported.

Time frame:
Baseline and week 12
Reported as:
Mean · microgram per milliliter (ug/mL)
Change From Baseline in Plasma Concentration of Bone Alkaline Phosphatase (BALP) at Week 12
microgram per milliliter (ug/mL)PlaceboFezolinetant
Change From Baseline in Plasma Concentration of Bone Alkaline Phosphatase (BALP) at Week 122.9 ± 5.431.7 ± 3.19
SecondaryChange From Baseline in Plasma Concentration of Carboxy-terminal Telopeptide of Type I Collagen (CTX) at Week 12

Change from baseline in plasma concentration of CTX was reported.

Time frame:
Baseline and week 12
Reported as:
Mean · ug/mL
Change From Baseline in Plasma Concentration of Carboxy-terminal Telopeptide of Type I Collagen (CTX) at Week 12
ug/mLPlaceboFezolinetant
Change From Baseline in Plasma Concentration of Carboxy-terminal Telopeptide of Type I Collagen (CTX) at Week 12-0.021 ± 0.12780.001 ± 0.1356

Adverse events

Collected over From first dose of study drug until end of the study (Up to week 15). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/44 (0%)1/44 (2.3%)18/44 (40.9%)
Fezolinetant0/43 (0%)0/43 (0%)18/43 (41.9%)
Most frequent serious events
Most frequent serious events
EventPlaceboFezolinetant
Upper limb fractureInjury, poisoning and procedural complications1/440/43
Most frequent other events
Most frequent other events
EventPlaceboFezolinetant
HeadacheNervous system disorders6/447/43
NasopharyngitisInfections and infestations4/442/43
PalpitationsCardiac disorders2/443/43
DiarrhoeaGastrointestinal disorders0/443/43
FatigueGeneral disorders0/443/43
InfluenzaInfections and infestations1/443/43
ArthritisMusculoskeletal and connective tissue disorders3/440/43
Back painMusculoskeletal and connective tissue disorders3/440/43

Baseline characteristics

Safety population was defined as all participants who were randomized into the study and received at least one dose of the study medication.

Age, Continuous
Age, Continuous(Years)PlaceboFezolinetantTotal
Mean53.7 ± 4.2553.3 ± 4.0353.5 ± 4.12
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboFezolinetantTotal
Female444387
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboFezolinetantTotal
Hispanic or Latino112
Not Hispanic or Latino424284
Unknown or Not Reported101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboFezolinetantTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White444286
More than one race011
Unknown or Not Reported000
Weekly General Hot Flash Score
Weekly General Hot Flash Score(Score on a scale)PlaceboFezolinetantTotal
Mean25.76 ± 10.2628.76 ± 13.3927.24 ± 11.93
08

Study locations

8 sites
  • Site BE32004
    Brussels, 1000, Belgium
  • Site BE32003
    Genk, 3600, Belgium
  • Site BE32001
    Gent, 9000, Belgium
  • Site BE32006
    Jette, 1090, Belgium
  • Site BE32005
    Kraainem, 1950, Belgium
  • Site BE32007
    Leuven, Belgium
  • Site BE32008
    Mons, 7000, Belgium
  • Site BE32009
    Tienen, 3300, Belgium
09

References and documents

Publications

  • Depypere H, Timmerman D, Donders G, Sieprath P, Ramael S, Combalbert J, Hoveyda HR, Fraser GL. Treatment of Menopausal Vasomotor Symptoms With Fezolinetant, a Neurokinin 3 Receptor Antagonist: A Phase 2a Trial. J Clin Endocrinol Metab. 2019 Dec 1;104(12):5893-5905. doi: 10.1210/jc.2019-00677. PubMed 31415087 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2015 to primary completion in Sep 2016, 12 months.

Results were first posted in Jul 2023, 6 years 10 months after primary completion. A results delay was requested in Jul 2022.

Of 24 phase 2 interventional studies under Hot Flashes, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 54. This study's 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2022
First posted
Jun 15, 2022
StartActual
Sep 21, 2015
Primary completionActual
Sep 21, 2016
CompletionActual
Oct 6, 2016
Results delay requested
Jul 5, 2022
Results first posted
Jul 25, 2023
Last update
Nov 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05419908
Lead sponsor
Ogeda S.A.
Responsible party
Sponsor
First posted
Jun 15, 2022
Start date
Sep 21, 2015
Primary completion
Sep 21, 2016
Completion
Oct 6, 2016
Results posted
Jul 25, 2023
Last update
Nov 27, 2024

Study contacts

Medical Expert
study director · Ogeda S.A.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fezolinetant

Start the discussion